press
Interview with Christoph Kausch in biotechandmoney
May 02, 2018 + Jessica Di Palo
5 Min read
Dr Christoph Kausch, Managing Partner at MTIP, talks to Biotech and Money about the firm’s ambitions and its commitment to environmental, social, and governance values.
INVESTORVIEW: COMMITTING TO SOCIAL RESPONSIBILITY IN HEALTHCARE INVESTMENT
Swiss healthcare-focused venture capital firm MTIP is in the process of building a portfolio of digital health and medical technologies companies after closing its first CHF60 million fund in 2017. Dr. Christoph Kausch, Founding Partner and Chief Executive Officer at MTIP, talks to Biotech and Money about the firm’s ambitions and its commitment to environmental, social, and governance values.
Download the article here.
fun fact: bioandtechnology got rebranded to LSX Leaders. visit their website to learn more: www.lsxleaders.com
Share the Article
Leading brands revolutionize care journeys with Lumeon
How Lumeon orchestrates care journey
Trialbee – our hero in patient matching and recruiting for clinical trials
Trialbee - patient matching and recruiting
Digital healthcare: patient-first?
Digital Healthcare Report 2021 in collaboration with Dealroom and INKEF Capital
SFDR – How does MTIP approach the EU’s Sustainable Disclosure Regulation?
New SFDR obligations
MTIP Announces Strong First Closing of Fund II to drive Healthtech Innovation
First Closing of Fund II
MTIP invests in Koa Health to make mental health treatment more accessible
New investment in Koa Health
MTIP scored fantastic grades in the UNPRI assessment report of 2020
UNPRI Report grades 2020
4 Health VCs Share Their Business Priorities and What is Next
Interview Techtour
TytoCare closes $50 million round as the demand for telehealth accelerates
TytoCare closes new round
The digital healthtech sector is expanding – and so are we!
Two new empolyees start in April
MTIP has sucessfully exited Blueprint Genetics
Blueprint exit January 2020
Whitepaper: A positive prognosis for the future of healthtech
Our first Whitepaper
Elite Summit 2019 – Interview with our Managing Partner Christoph Kausch
Elite Summit 2019
New MTIP investment in Quanta Dialysis Technologies
New investment in Quanta
Interview with Christoph Kausch in biotechandmoney
interview Bioandtechnology
New MTIP investment – Nitinotes Series A Round
New investment in Nitinotes
New investment in an Israeli based digital health company TytoCare
New investment in TytoCare